Mesoblast Ltd News

Mesoblast Ltd: Class Action Resolution

Aug 21 05:07 ET

Mesoblast Ltd: Quarterly Activities/Appendix 4C Cash Flow Report

Jul 30 19:53 ET

Mesoblast Ltd: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L

Jul 23 00:18 ET

Mesoblast Ltd: Confirmatory Phase 3 Back Pain Trial Actively Enrols

Jul 21 19:07 ET

Mesoblast Ltd: Appendix 3Y for Philip Krause

Jul 12 03:27 ET

Mesoblast Ltd: Mesoblast Resubmits BLA with FDA for Ryoncil Approval

Jul 8 19:55 ET

Mesoblast Ltd: Mesoblast to File BLA for Ryoncil FDA Approval Next Week

Jul 1 01:00 ET

Mesoblast Ltd: Mesoblast Corporate Presentation at Investor Conference

Jun 2 19:27 ET

Mesoblast Ltd: Appendix 3Y for Eric Rose

May 9 19:22 ET

Mesoblast Ltd: Appendix 3Y for Eric Rose

May 2 19:49 ET

Mesoblast Ltd: Quarterly Activities/Appendix 4C Cash Flow Report

Apr 29 19:59 ET

Mesoblast Ltd: Mesoblast Chair Transition

Apr 29 19:47 ET

Mesoblast Ltd: Appendix 3Y for Jane Bell

Apr 15 19:18 ET

Mesoblast Ltd: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA

Mar 25 22:05 ET

Mesoblast Ltd: Pause in Trading

Mar 25 18:52 ET

Mesoblast Ltd: FDA Supports Accelerated Approval Pathway for Heart Failure

Mar 10 18:57 ET

Mesoblast Ltd: Mesoblast 2024 Half Year Financial Results Webcast

Feb 26 01:00 ET

Mesoblast Ltd: FDA Grants Orphan Drug Designation for Revascor

Feb 14 18:46 ET

Mesoblast Ltd: Quarterly Activities/Appendix 4C Cash Flow Report

Jan 30 20:39 ET

Mesoblast Ltd: FDA Grants Rare Pediatric Disease Designation for Revascor

Jan 18 17:56 ET